The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.

Dutta, Debashis; Chandra, Goutam; Mohanakumar, Kochupurackal P

Dutta, Debashis; Chandra, Goutam; Mohanakumar, Kochupurackal P.

Afiliação

Dutta D; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Chandra G; Inter University Centre for Biomedical Research & Super Speciality Hospital, Mahatma Gandhi University Campus at Thalappady, Kottayam, Kerala, India.
Mohanakumar KP; Inter University Centre for Biomedical Research & Super Speciality Hospital, Mahatma Gandhi University Campus at Thalappady, Kottayam, Kerala, India.

J Neurochem ; 153(5): 545-548, 2020 06.

Article em En | MEDLINE | ID: mdl-32128827

Assuntos

Atrofia Muscular Espinal/líquido cefalorraquidiano; Atrofia Muscular Espinal/tratamento farmacológico; Oligonucleotídeos/uso terapêutico; Proteômica/métodos; Biomarcadores/líquido cefalorraquidiano; Humanos; Atrofia Muscular Espinal/genética; Proteômica/tendências

Palavras-chave

antisense oligonucleotide; cerebrospinal fluid proteome; nusinersen; spinal muscular atrophy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Atrofia Muscular Espinal / Proteômica Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google